Field of the Invention
The present invention relates generally to an ultrasonic catheter and more specifically to an ultrasonic catheter configured to deliver ultrasonic energy and a therapeutic compound to a treatment site.
Description of the Related Art
Several medical applications use ultrasonic energy. For example, U.S. Pat. Nos. 4,821,740, 4,953,565 and 5,007,438 disclose the use of ultrasonic energy to enhance the effect of various therapeutic compounds. An ultrasonic catheter can be used to deliver ultrasonic energy and a therapeutic compound to a treatment site in a patient's body. Such an ultrasonic catheter typically includes an ultrasound assembly configured to generate ultrasonic energy and a fluid delivery lumen for delivering the therapeutic compound to the treatment site.
As taught in U.S. Pat. No. 6,001,069, such ultrasonic catheters can be used to treat human blood vessels that have become partially or completely occluded by plaque, thrombi, emboli or other substances that reduce the blood carrying capacity of the vessel. To remove or reduce the occlusion, the ultrasonic catheter is used to deliver solutions containing dissolution compounds directly to the occlusion site. Ultrasonic energy generated by the ultrasound assembly enhances the therapeutic effect of the dissolution compounds. For example, in one application of such an ultrasonic catheter, an ultrasound-enhanced thrombolytic therapy dissolves blood clots in arteries and veins in the treatment of diseases such as peripheral arterial occlusion or deep vein thrombosis. In such applications, ultrasonic energy enhances thrombolysis with agents such as urokinase, tissue plasminogen activator (“TPA”) and the like.
Ultrasonic catheters can also be used to enhance gene therapy at a treatment site within the patient's body. For example, U.S. Pat. No. 6,135,976 discloses an ultrasonic catheter having one or more expandable sections capable of occluding a section of a body lumen, such as a blood vessel. A gene therapy composition is then delivered to the occluded vessel through the catheter fluid delivery lumen. Ultrasonic energy generated by the ultrasound assembly is applied to the occluded vessel, thereby enhancing the delivery of a genetic composition into the cells of the occluded vessel.
Ultrasonic catheters can also be used to enhance delivery and activation of light activated drugs. For example, U.S. Pat. No. 6,176,842 discloses methods for using an ultrasonic catheter to treat biological tissues by delivering a light activated drug to the biological tissues and exposing the light activated drug to ultrasound energy.
In certain medical procedures, it is desirable to provide ultrasonic energy along a substantial length of a body lumen. For example, long segment peripheral arterial occlusions, such as those in the arteries of the leg, may have an axial length in the range of 10 to 50 cm. To date, it has been difficult to design an ultrasonic catheter capable of efficiently applying ultrasound energy over such lengths.
One method for emitting ultrasonic energy over such lengths is to provide the ultrasonic catheter with a plurality of ultrasonic transducers spaced along a distal region of the catheter. Such an arrangement faces several technical hurdles. For example, because the ultrasonic transducers are relatively rigid, the catheter may become too inflexible to be navigated through the lumens of the patient's body. One solution is to use smaller transducers. However, smaller transducers may not be capable of producing sufficient energy at the proper frequency to enhance the therapeutic affect of a therapeutic agent.
Another solution is disclosed in U.S. Pat. No. 6,296,610. This patent discloses a catheter with a plurality of transducers that are moved back and forth within the catheter through the treatment zone. However, this arrangement is generally undesirable because it requires a translation system for moving the ultrasonic elements within the catheter.
Additionally, for ease of manufacturing and reduced costs, it is generally desirable to use ultrasonic transducers that are in the form of rectangular bars as compared to, for example, cylindrical transducers. However, such arrangements should still generate a therapeutically effective ultrasonic energy field.
A need, therefore, exists for an improved ultrasonic catheter capable of providing ultrasonic energy over a substantial length of a body lumen with little or no movement of the ultrasonic elements within the patient during treatment. Such a catheter preferably uses flat rectangular ultrasonic transducers.
As such, according to one embodiment of the present invention, a catheter system for delivering ultrasonic energy and a therapeutic compound to a treatment site within a body lumen comprises a tubular body. The tubular body has a proximal end, a distal end and an energy delivery section positioned between the proximal end and the distal end. The catheter system further comprises a fluid delivery lumen extending at least partially through the tubular body. The fluid delivery lumen has at least one outlet in the energy delivery section. The catheter system further comprises an inner core configured for insertion into the tubular body. The inner core comprises an elongate electrical conductor having a plurality of flattened regions. Each flattened region has a first flat side and a second flat side opposite the first flat side. The inner core further comprises a plurality of ultrasound radiating members mounted in pairs to the flattened regions of the elongate electrical conductor. A first ultrasound radiating member is mounted to the first flat side of the elongate electrical conductor, and a second ultrasound radiating member is mounted to the second flat side of the elongate electrical conductor. The inner core further comprises wiring such that a voltage can be applied from the elongate electrical conductor across the first and second ultrasound radiating members. The first and second ultrasound radiating members can be driven simultaneously.
According to another embodiment of the present invention, a catheter system for delivering ultrasonic energy to a treatment site comprises a tubular body. The tubular body has a proximal end, a distal end and a treatment zone located between the distal end and the proximal end. The catheter system further comprises an ultrasonic assembly positioned within the treatment zone. The ultrasonic assembly comprises an electrical conductor and an ultrasonic transducer pair. The ultrasonic transducer pair includes a first ultrasound transducer having a first portion and a second ultrasound transducer having a second portion. The first portion of the first transducer and the second portion of the second transducer face each other and are electrically coupled to the electrical conductor.
According to another embodiment of the present invention, a catheter system for delivering ultrasonic energy to a treatment site comprises a tubular body. The tubular body has a proximal end, a distal end and a treatment zone located between the distal and proximal ends. The catheter system further comprises an ultrasonic assembly positioned within the treatment zone. The ultrasonic assembly comprises an electrical conductor and an ultrasonic transducer pair. The ultrasonic transducer pair includes a rectangular solid first ultrasonic element and a rectangular solid second ultrasonic element. The first and second ultrasonic elements are mounted on opposite sides of the electrical conductor.
According to another embodiment of the present invention, an apparatus comprises an elongate tubular body having a fluid delivery lumen. The apparatus further comprises an inner core configured for insertion into the tubular body. The inner core comprises a common wire and a plurality of ultrasound radiating members. The plurality of ultrasound radiating members are positioned and electrically coupled to the common wire in pairs. The apparatus further comprises a control system configured to drive each pair of ultrasound radiating members.
According to another embodiment of the present invention, a method of delivering ultrasonic energy and a therapeutic compound to a treatment site comprises providing a catheter with a plurality of ultrasound radiating members. The plurality of ultrasound radiating members are allocated into electrical groups comprising more than one ultrasound radiating member. The method further comprises independently driving each group of ultrasonic radiating members. The method further comprises delivering the therapeutic compound through the catheter to the treatment site.
According to another embodiment of the present invention, an ultrasonic catheter comprises a tubular body. The tubular body has a proximal end, a distal end and a treatment zone located between the distal end and the proximal end. The ultrasonic catheter further comprises a plurality of fluid delivery lumens defined within the tubular body. The ultrasonic catheter further comprises an inner core comprising at least one ultrasound radiating element. The ultrasonic catheter further comprises a plurality of cooling fluid channels defined between at least an inner surface of the tubular body and an outer surface of the inner core. Each cooling fluid channel is positioned generally radially between two fluid delivery lumens.
According to another embodiment of the present invention, an ultrasonic catheter system comprises a tubular body. The tubular body has a proximal end, a distal end and a treatment zone located between the distal end and the proximal end. The ultrasonic catheter system further comprises a fluid delivery lumen. The ultrasonic catheter system further comprises at least one ultrasound radiating element positioned in the treatment zone. The ultrasonic catheter system further comprises wiring electrically coupled to the at least one ultrasound radiating element. The wiring extends through the tubular body and terminates at a connector. The ultrasonic catheter system further comprises a control system. The control system comprises external circuitry and an isolation pod. The isolation pod is configured to be electrically connected to the connector. The isolation pod is also positioned between the tubular body and the external system. The isolation pod comprises an isolation barrier and circuitry for driving the ultrasound radiating element.
According to another embodiment of the present invention, an ultrasonic catheter comprises a tubular body. The tubular body has a proximal end, a distal end and a treatment zone located between the distal end and the proximal end. The ultrasonic catheter further comprises at least one fluid delivery lumen incorporated into the tubular body. The ultrasonic catheter further comprises a plurality of ultrasound radiating members mounted within an inner core. The inner core is positioned within the tubular body such that at least one of the ultrasound radiating members is located within the treatment zone. The ultrasonic catheter further comprises means for independently driving each of the ultrasound transducers.
For purposes of summarizing the invention and the advantages achieved over the prior art, certain objects and advantages of the invention have been described above. It is to be understood that not necessarily all such objects or advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objects or advantages as may be taught or suggested herein.
All of these embodiments are intended to be within the scope of the invention herein disclosed. These and other embodiments of the present invention will become readily apparent to those skilled in the art from the following detailed description of the preferred embodiments having reference to the attached figures, the invention not being limited to any particular preferred embodiment(s) disclosed.
As described above, it is desired to provide an ultrasonic catheter having various features and advantages. Examples of such features and advantages include the ability to apply ultrasonic energy to a treatment site. In another embodiments, the catheter has the ability to deliver a therapeutic compound to the treatment site. Preferred embodiments of an ultrasonic catheter having certain of these features and advantages are described herein. Methods of using such an ultrasonic catheter are also described herein.
The ultrasonic catheters described herein can be used to enhance the therapeutic effects of therapeutic compounds at a treatment site within a patient's body. As used herein, the term “therapeutic compound” refers broadly, without limitation, to a drug, medicament, dissolution compound, genetic material or any other substance capable of effecting physiological functions. Additionally, any mixture comprising any such substances is encompassed within this definition of “therapeutic compound”, as well as any substance falling within the ordinary meaning of these terms. The enhancement of the effects of therapeutic compounds using ultrasonic energy is described in U.S. Pat. Nos. 5,318,014, 5,362,309, 5,474,531, 5,628,728, 6,001,069 and 6,210,356, the entire disclosure of which are hereby incorporated by herein by reference. Specifically, for applications that treat human blood vessels that have become partially or completely occluded by plaque, thrombi, emboli or other substances that reduce the blood carrying capacity of a vessel, suitable therapeutic compounds include, but are not limited to, an aqueous solution containing Heparin, Uronkinase, Streptokinase, TPA and BB-10153 (manufactured by British Biotech, Oxford, UK).
Certain features and aspects of the ultrasonic catheters disclosed herein may also find utility in applications where the ultrasonic energy itself provides a therapeutic effect. Examples of such therapeutic effects include preventing or reducing stenosis and/or restenosis; tissue ablation, abrasion or disruption; promoting temporary or permanent physiological changes in intracellular or intercellular structures; and rupturing micro-balloons or micro-bubbles for therapeutic compound delivery. Further information about such methods can be found in U.S. Pat. Nos. 5,261,291 and 5,431,663, the entire disclosure of which are hereby incorporated by herein by reference.
The ultrasonic catheters described herein are configured for applying ultrasonic energy over a substantial length of a body lumen, such as, for example, the larger vessels located in the leg. However, it should be appreciated that certain features and aspects of the present invention may be applied to catheters configured to be inserted into the small cerebral vessels, in solid tissues, in duct systems and in body cavities. Additional embodiments that may be combined with certain features and aspects of the embodiments described herein are described in U.S. patent application, Attorney Docket EKOS.026A, entitled “Ultrasound Assembly For Use With A Catheter” and filed Nov. 7, 2002, the entire disclosure of which is hereby incorporated herein by reference.
With initial reference to
As illustrated in
For example, in a preferred embodiment the proximal region 14 of the tubular body 12 comprises a material that has sufficient flexibility, kink resistance, rigidity and structural support to push the energy delivery section 18 through the patient's vasculature to a treatment site. Examples of such materials include, but are not limited to, extruded polytetrafluoroethylene (“PTFE”), polyethylenes (“PE”), polyamides and other similar materials. In certain embodiments, the proximal region 14 of the tubular body 12 is reinforced by braiding, mesh or other constructions to provide increased kink resistance and pushability. For example, nickel titanium or stainless steel wires can be placed along or incorporated into the tubular body 12 to reduce kinking.
In an embodiment configured for treating thrombus in the arteries of the leg, the tubular body 12 has an outside diameter between about 0.060 inches and about 0.075 inches. In another embodiment, the tubular body 12 has an outside diameter of about 0.071 inches. In certain embodiments, the tubular body 12 has an axial length of approximately 105 centimeters, although other lengths may by appropriate for other applications.
The energy delivery section 18 of the tubular body 12 preferably comprises a material that is thinner than the material comprising the proximal region 14 of the tubular body 12 or a material that has a greater acoustic transparency. Thinner materials generally have greater acoustic transparency than thicker materials. Suitable materials for the energy delivery section 18 include, but are not limited to, high or low density polyethylenes, urethanes, nylons, and the like. In certain modified embodiments, the energy delivery section 18 may be formed from the same material or a material of the same thickness as the proximal region 18.
In certain embodiments, the tubular body 12 is divided into at least three sections of varying stiffness. The first section, which preferably includes the proximal region 14, has a relatively higher stiffness. The second section, which is located in an intermediate region between the proximal region 14 and the distal region 15 of the tubular body 12, has a relatively lower stiffness. This configuration further facilitates movement and placement of the catheter 10. The third section, which preferably includes the energy delivery section 18, is generally lower stiffness than the second section in spite of the presence of the ultrasound radiating members 40.
In certain embodiments, the central lumen 51 has a minimum diameter greater than about 0.030 inches. In another embodiment, the central lumen 51 has a minimum diameter greater than about 0.037 inches. In one preferred embodiment, the fluid delivery lumens 30 have dimensions of about 0.026 inches wide by about 0.0075 inches high, although other dimensions may be used in other applications.
As described above, the central lumen 51 preferably extends through the length of the tubular body 12. As illustrated in
The central lumen 51 is configured to receive an elongate inner core 34 of which a preferred embodiment is illustrated in
As shown in the cross-section illustrated in
Still referring to
In a preferred embodiment, the ultrasound assembly 42 comprises a plurality of ultrasound radiating members 40 that are divided into one or more groups. For example,
As used herein, the terms “ultrasonic energy”, “ultrasound” and “ultrasonic” are broad terms, having their ordinary meanings, and further refer to, without limitation, mechanical energy transferred through longitudinal pressure or compression waves. Ultrasonic energy can be emitted as continuous or pulsed waves, depending on the requirements of a particular application. Additionally, ultrasonic energy can be emitted in waveforms having various shapes, such as sinusoidal waves, triangle waves, square waves, or other wave forms. Ultrasonic energy includes sound waves. In certain embodiments, the ultrasonic energy has a frequency between about 20 kHz and about 20 MHz. For example, in one embodiment, the waves have a frequency between about 500 kHz and about 20 MHz. In another embodiment, the waves have a frequency between about 1 MHz and about 3 MHz. In yet another embodiment, the waves have a frequency of about 2 MHz. The average acoustic power is between about 0.01 watts and 300 watts. In one embodiment, the average acoustic power is about 15 watts.
As used herein, the term “ultrasound radiating member” refers to any apparatus capable of producing ultrasonic energy. For example, in one embodiment, an ultrasound radiating member comprises an ultrasonic transducer, which converts electrical energy into ultrasonic energy. A suitable example of an ultrasonic transducer for generating ultrasonic energy from electrical energy includes, but is not limited to, piezoelectric ceramic oscillators. Piezoelectric ceramics typically comprise a crystalline material, such as quartz, that change shape when an electrical current is applied to the material. This change in shape, made oscillatory by an oscillating driving signal, creates ultrasonic sound waves. In other embodiments, ultrasonic energy can be generated by an ultrasonic transducer that is remote from the ultrasound radiating member, and the ultrasonic energy can be transmitted, via, for example, a wire that is coupled to the ultrasound radiating member.
Still referring to
Referring now to
Referring still to
In a modified embodiment, such as illustrated in
One of ordinary skill in the art will recognize that the wiring arrangement described above can be modified to allow each group G1, G2, G3, G4, G5 to be independently powered. Specifically, by providing a separate power source within the control system 100 for each group, each group can be individually turned on or off, or can be driven with an individualized power. This provides the advantage of allowing the delivery of ultrasonic energy to be “turned off” in regions of the treatment site where treatment is complete, thus preventing deleterious or unnecessary ultrasonic energy to be applied to the patient.
The embodiments described above, and illustrated in
In a preferred embodiment, the ultrasound radiating members 40 comprise rectangular lead zirconate titanate (“PZT”) ultrasound transducers that have dimensions of about 0.017 inches by about 0.010 inches by about 0.080 inches. In other embodiments, other configuration may be used. For example, disc-shaped ultrasound radiating members 40 can be used in other embodiments. In a preferred embodiment, the common wire 108 comprises copper, and is about 0.005 inches thick, although other electrically conductive materials and other dimensions can be used in other embodiments. Lead wires 110 are preferably 36 gauge electrical conductors, while positive contact wires 112 are preferably 42 gauge electrical conductors. However, one of ordinary skill in the art will recognize that other wire gauges can be used in other embodiments.
As described above, suitable frequencies for the ultrasound radiating member 40 include, but are not limited to, from about 20 kHz to about 20 MHz. In one embodiment, the frequency is between about 500 kHz and 20 MHz, and in another embodiment 1 MHz and 3 MHz. In yet another embodiment, the ultrasound radiating members 40 are operated with a frequency of about 2 MHz.
By evenly spacing the fluid delivery lumens 30 around the circumference of the tubular body 12, as illustrated in
For example, in one embodiment in which the fluid delivery ports 58 have similar sizes along the length of the tubular body 12, the fluid delivery ports 58 have a diameter between about 0.0005 inches to about 0.0050 inches. In another embodiment in which the size of the fluid delivery ports 58 changes along the length of the tubular body 12, the fluid delivery ports 58 have a diameter between about 0.001 inches to about 0.005 inches in the proximal region of the energy delivery section 18, and between about 0.005 inches to 0.0020 inches in the distal region of the energy delivery section 18. The increase in size between adjacent fluid delivery ports 58 depends on the material comprising the tubular body 12, and on the size of the fluid delivery lumen 30. The fluid delivery ports 58 can be created in the tubular body 12 by punching, drilling, burning or ablating (such as with a laser), or by any other suitable method. Therapeutic compound flow along the length of the tubular body 12 can also be increased by increasing the density of the fluid delivery ports 58 toward the distal region 15 of the tubular body 12.
It should be appreciated that it may be desirable to provide non-uniform fluid flow from the fluid delivery ports 58 to the treatment site. In such embodiment, the size, location and geometry of the fluid delivery ports 58 can be selected to provide such non-uniform fluid flow.
Referring still to
In a preferred embodiment, the inner core 34 can be rotated or moved within the tubular body 12. Specifically, movement of the inner core 34 can be accomplished by maneuvering the proximal hub 37 while holding the backend hub 33 stationary. The inner core outer body 35 is at least partially constructed from a material that provides enough structural support to permit movement of the inner core 34 within the tubular body 12 without kinking of the tubular body 12. Additionally, the inner core outer body 35 preferably comprises a material having the ability to transmit torque. Suitable materials for the inner core outer body 35 include, but are not limited to, polyimides, polyesters, polyurethanes, thermoplastic elastomers and braided polyimides.
In a preferred embodiment, the fluid delivery lumens 30 and the cooling fluid lumens 44 are open at the distal end of the tubular body 12, thereby allowing the therapeutic compound and the cooling fluid to pass into the patient's vasculature at the distal exit port. Or, if desired, the fluid delivery lumens 30 can be selectively occluded at the distal end of the tubular body 12, thereby providing additional hydraulic pressure to drive the therapeutic compound out of the fluid delivery ports 58. In either configuration, the inner core 34 can prevented from passing through the distal exit port by making providing the inner core 34 with a length that is less than the length of the tubular body. In other embodiments, a protrusion is formed on the internal side of the tubular body in the distal region 15, thereby preventing the inner core 34 from passing through the distal exit port.
In still other embodiments, the catheter 10 further comprises an occlusion device (not shown) positioned at the distal exit port 29. The occlusion device preferably has a reduced inner diameter that can accommodate a guidewire, but that is less than the inner diameter of the central lumen 51. Thus, the inner core 34 is prevented from extending through the occlusion device and out the distal exit port 29. For example, suitable inner diameters for the occlusion device include, but are not limited to, about 0.005 inches to about 0.050 inches. In other embodiments, the occlusion device has a closed end, thus preventing cooling fluid from leaving the catheter 10, and instead recirculating to the proximal region 14 of the tubular body 12. These and other cooling fluid flow configurations permit the power provided to the ultrasound assembly 42 to be increased in proportion to the cooling fluid flow rate. Additionally, certain cooling fluid flow configurations can reduce exposure of the patient's body to cooling fluids.
In certain embodiments, as illustrated in
In other embodiments, each temperature sensor 20 is independently wired. In such embodiments, 2n wires through the tubular body 12 to independently sense the temperature at n independent temperature sensors 20. In still other embodiments, the flexibility of the tubular body 12 can be improved by using fiber optic based temperature sensors 20. In such embodiments, flexibility can be improved because only n fiber optic members are used to sense the temperature at n independent temperature sensors 20.
The feedback control system 68 preferably comprises an energy source 70, power circuits 72 and a power calculation device 74 that is coupled to the ultrasound radiating members 40. A temperature measurement device 76 is coupled to the temperature sensors 20 in the tubular body 12. A processing unit 78 is coupled to the power calculation device 74, the power circuits 72 and a user interface and display 80.
In operation, the temperature at each temperature sensor 20 is determined by the temperature measurement device 76. The processing unit 78 receives each determined temperature from the temperature measurement device 76. The determined temperature can then be displayed to the user at the user interface and display 80.
The processing unit 78 comprises logic for generating a temperature control signal. The temperature control signal is proportional to the difference between the measured temperature and a desired temperature. The desired temperature can be determined by the user (at set at the user interface and display 80) or can be preset within the processing unit 78.
The temperature control signal is received by the power circuits 72. The power circuits 72 are preferably configured to adjust the power level, voltage, phase and/or current of the electrical energy supplied to the ultrasound radiating members 40 from the energy source 70. For example, when the temperature control signal is above a particular level, the power supplied to a particular group of ultrasound radiating members 40 is preferably reduced in response to that temperature control signal. Similarly, when the temperature control signal is below a particular level, the power supplied to a particular group of ultrasound radiating members 40 is preferably increased in response to that temperature control signal. After each power adjustment, the processing unit 78 preferably monitors the temperature sensors 20 and produces another temperature control signal which is received by the power circuits 72.
The processing unit 78 preferably further comprises safety control logic. The safety control logic detects when the temperature at a temperature sensor 20 has exceeded a safety threshold. The processing unit 78 can then provide a temperature control signal which causes the power circuits 72 to stop the delivery of energy from the energy source 70 to that particular group of ultrasound radiating members 40.
Because, in certain embodiments, the ultrasound radiating members 40 are mobile relative to the temperature sensors 20, it can be unclear which group of ultrasound radiating members 40 should have a power, voltage, phase and/or current level adjustment. Consequently, each group of ultrasound radiating member 40 can be identically adjusted in certain embodiments. In a modified embodiment, the power, voltage, phase, and/or current supplied to each group of ultrasound radiating members 40 is adjusted in response to the temperature sensor 20 which indicates the highest temperature. Making voltage, phase and/or current adjustments in response to the temperature sensed by the temperature sensor 20 indicating the highest temperature can reduce overheating of the treatment site.
The processing unit 78 also receives a power signal from a power calculation device 74. The power signal can be used to determine the power being received by each group of ultrasound radiating members 40. The determined power can then be displayed to the user on the user interface and display 80.
As described above, the feedback control system 68 can be configured to maintain tissue adjacent to the energy delivery section 18 below a desired temperature. For example, it is generally desirable to prevent tissue at a treatment site from increasing more than 6° C. As described above, the ultrasound radiating members 40 can be electrically connected such that each group of ultrasound radiating members 40 generates an independent output. In certain embodiments, the output from the power circuit maintains a selected energy for each group of ultrasound radiating members 40 for a selected length of time.
The processing unit 78 can comprise a digital or analog controller, such as for example a computer with software. When the processing unit 78 is a computer it can include a central processing unit (“CPU”) coupled through a system bus. As is well known in the art, the user interface and display 80 can comprise a mouse, a keyboard, a disk drive, a display monitor, a nonvolatile memory system, or any another. Also preferably coupled to the bus is a program memory and a data memory.
In lieu of the series of power adjustments described above, a profile of the power to be delivered to each group of ultrasound radiating members 40 can be incorporated into the processing unit 78, such that a preset amount of ultrasonic energy to be delivered is pre-profiled. In such embodiments, the power delivered to each group of ultrasound radiating members 40 can then be adjusted according to the preset profiles.
The ultrasound radiating members are preferably operated in a pulsed mode. For example, in one embodiment, the time average power supplied to the ultrasound radiating members is preferably between about 0.1 watts and 2 watts and more preferably between about 0.5 watts and 1.5 watts. In certain preferred embodiments, the time average power is approximately 0.6 watts or 1.2 watts. The duty cycle is preferably between about 1% and 50% and more preferably between about 5% and 25%. In certain preferred embodiments, the duty ratio is approximately 7.5% or 15%. The pulse averaged power is preferably between about 0.1 watts and 20 watts and more preferably between approximately 5 watts and 20 watts. In certain preferred embodiments, the pulse averaged power is approximately 8 watts and 16 watts. The amplitude during each pulse can be constant or varied.
In one embodiment, the pulse repetition rate is preferably between about 5 Hz and 150 Hz and more preferably between about 10 Hz and 50 Hz. In certain preferred embodiments, the pulse repetition rate is approximately 30 Hz. The pulse duration is preferably between about 1 millisecond and 50 milliseconds and more preferably between about 1 millisecond and 25 milliseconds. In certain preferred embodiments, the pulse duration is approximately 2.5 milliseconds or 5 milliseconds.
In one particular embodiment, the transducers are operated at an average power of approximately 0.6 watts, a duty cycle of approximately 7.5%, a pulse repetition rate of 30 Hz, a pulse average electrical power of approximately 8 watts and a pulse duration of approximately 2.5 milliseconds.
The ultrasound radiating member used with the electrical parameters described herein preferably has an acoustic efficiency greater than 50% and more preferably greater than 75%. The ultrasound radiating member can be formed a variety of shapes, such as, cylindrical (solid or hollow), flat, bar, triangular, and the like. The length of the ultrasound radiating member is preferably between about 0.1 cm and about 0.5 cm. The thickness or diameter of the ultrasound radiating members is preferably between about 0.02 cm and about 0.2 cm.
As illustrated in
As illustrated in
As illustrated in
In a certain embodiment, the ultrasound assembly 42 comprises sixty ultrasound radiating members 40 spaced over a length of approximately 30 to 50 cm. In such embodiments, the catheter 10 can be used to treat an elongate clot 90 without requiring movement of or repositioning of the catheter 10 during the treatment. However, it will be appreciated that in modified embodiments the inner core 34 can be moved or rotated within the tubular body 12 during the treatment. Such movement can be accomplished by maneuvering the proximal hub 37 of the inner core 34 while holding the backend hub 33 stationary.
Referring again to
The cooling fluid can be delivered before, after, during or intermittently with the delivery of ultrasonic energy. Similarly, the therapeutic compound can be delivered before, after, during or intermittently with the delivery of ultrasonic energy. Consequently, the steps illustrated in
To reduce electric current leakage through the patient's body to ground, in certain embodiments the control system 100 may comprise an isolation pod 200.
The isolation pod 200 comprises an isolation barrier 228 configured to reduce or eliminate unwanted electrical current flow through the patient's body. For example, in the illustrated embodiment, two transformers 256, 276 form an isolation barrier between the external control circuitry 100 and the certain components of the isolation pod 200.
Referring still to
The external control circuitry 100 provides a radio frequency signal 224 for driving the ultrasound assembly 42. The radio frequency signal 224 operates in the ultrasonic frequency range, and is tuned to a frequency that activates the ultrasound radiating members 40 in the inner core 34. The radio frequency signal 224 is electromagnetically coupled to the isolation pod 200 using a transformer 256. The dielectric layers of the transformer 256 form an isolation barrier. This isolation barrier substantially prevents electrical current from flowing from the isolation pod 200, through the patient's body, and back into the isolation pod 200. By electromagnetically coupling the driving radio frequency signal to the isolation pod 200, the current loop is broken and electric current is thereby prevented from flowing through the patient's body.
In the embodiment illustrated in
The exemplary isolation pod 200 includes circuitry to enable matching the output impedance of the radio frequency amplifier to the input impedance of the ultrasound radiating members. For example, many radio frequency amplifiers have an output impedance of about 50Ω. To maximize power efficiency, the isolation pod 200 attempts to match the impedance by providing a substantially equivalent 50Ω at the input.
Still referring to
Changing the turns ratio of the coupling transformer 256 also affects the amplitude of the current passing through the ultrasonic assembly 42. As needed, the external control circuitry 100 compensates for these changes in amplitude for example by driving the radio frequency signal at different levels.
The embodiment illustrated in
In one embodiment, tuning information is determined for a catheter at the time of manufacture. The tuning information is then embedded into the catheter, such as by saving the tuning information in an identification programmable read-only memory (“PROM”) 254. Alternatively, the serial number or other identifying indicia of the catheter together with the tuning information is entered into a database. The isolation pod 200 then retrieves the tuning information from the database and appropriately adjusts the tuning circuitry to the catheter that is attached to the isolation pod 200.
In another embodiment, the isolation pod 200 includes internal circuitry to detect the impedance of the ultrasound assembly 42 in the catheter and adjusts the tuning circuitry appropriately.
In one embodiment, one pair of switches is in the (closed, open) setting and the remaining four pairs of switches are in the (open, closed) setting. In this such embodiments, four ultrasound radiating members are active at a time. The remaining six ultrasound radiating members have both terminals short circuited, so they are not active.
Alternatively, when all of the switches connected to the second terminal 280 are in the (closed) setting, each switch connected to the first terminal 278 activates a bank of three ultrasound radiating members. For example, if all the switches to the second terminal 280 are closed, closing the switch for the ultrasound radiating member driving line 352 activates three ultrasound radiating members 372, 374, 376, 378. Other banks of three ultrasound radiating members are activated by the closing switches for the remaining three ultrasound radiating member driving lines 354, 356, 358. Again, the banks are independently operable, so zero, one, two, or three banks can be active at any given time.
It is not necessary to activate the ultrasound radiating members in banks, because the switches can be individually controlled. A total of 27=128 driving combinations are possible. The non-bank configurations include voltage divider circuits, so all of the ultrasound radiating members are not driven at full strength in these configurations.
One of ordinary skill in the art will understand that the illustrated embodiments are exemplary and that the catheter design is not limited to the illustrated configurations. For example, the catheter may include different numbers of ultrasound radiating members, ultrasound radiating member driving lines, or switches. Some or all of the switches may alternately be included as part of the catheter.
A catheter may include ultrasound radiating members tuned to resonate at multiple frequencies. Ultrasound radiating members having the same resonant frequency can be selected individually or in groups. Alternatively, ultrasound radiating members having different resonant frequencies can be driven by the same driving signal. In such embodiments, the amount of ultrasonic energy delivered by an ultrasound radiating member depends in part on the frequency at which the ultrasound radiating member is driven.
Controlling the amplitude and frequency of the driving signal and arranging the placement of the ultrasound radiating members allows the catheter to deliver appropriate ultrasonic energy levels to the treatment site. In certain applications, it is desired that the catheter delivers a uniform dose of ultrasonic energy to the treatment site. In other applications, it is desired to deliver greater amounts of ultrasonic energy or ultrasonic energy of a different frequency to different portions of the treatment site. The individual control of the ultrasound radiating members described above allows the ultrasound assembly to deliver the appropriate amount and quality of ultrasonic energy to the treatment site.
For example, piezoelectric transducers can be used to generate ultrasonic energy. Piezoelectric transducers produce ultrasonic energy when an electric voltage is applied to certain crystalline structures. The characteristics of the ultrasonic energy generated by a piezoelectric transducer is determined by the crystalline structure of the transducer, as well as by the frequency and voltage at which the transducer is driven.
As shown in
As discussed above, and as shown in
Because there may be some variance in the diodes when used as temperatures sensors, one embodiment utilizes a calibration process. For example, calibration data may be included in the ID PROM 254. In modified embodiments, the diodes can be calibrated against an ambient temperature reading.
In other embodiments, the temperature sensors 20 monitor the temperature of the treatment site at which the catheter is operating. For example, in one embodiment a temperature sensor is placed near a ultrasound radiating member to measure the temperature of the tissue near the catheter. In other embodiments, a temperature sensor is positioned between two ultrasound radiating members to measure the average energy delivered by the ultrasound assembly.
Referring again to the isolation pod 200 illustrated in
Still referring to
As illustrated in
Still referring to
In the embodiment illustrated in
In another embodiment, all or part of the electronics for driving the ultrasound radiating members is housed within the backend hub 33. Similarly, all or part of the electronics for processing the temperature signals is can be housed within the backend hub 33 as well. However, because certain catheters described herein are intended to be disposable, the cost of the catheter can be reduced by minimizing the amount of electronics contained within the catheter. Additionally, reducing the amount of electronics contained within the catheter also reduces the catheter size. Thus, catheters configured to operate in narrow passages such as small vessels will also benefit from the reduction of electronics contained within the catheter. Therefore, in other embodiments, minimal electronics is incorporated within the catheter.
A user may connect multiple types of catheters to a single isolation pod 200. To identify the type of catheter connected to the isolation pod 200, the catheter preferably includes electronics containing an identifying code. The identifying code conveys information such as the type of catheter, the serial number of the catheter, the manufacturing location of the catheter, the date of manufacture, or other identifying information. In one embodiment, the circuitry for storing the identifying code is a PROM 254. Other types of memory such as flash memory or non-volatile random access memory (“RAM”) can also serve to identify the catheter. Electronics such as switches, jumpers, diodes, or hard wired connections can also serve to identify the catheter. One of ordinary skill in the art will recognize that other circuits not disclosed herein will also provide identification of the catheter.
Information contained on the identification PROM 254 can include, for example, the length of the catheter, the length of the treatment zone, the number of ultrasound radiating members in the catheter, the ultrasound radiating member layout, the resonant frequency of the ultrasound radiating members, tuning information for the ultrasound radiating members, compensation and/or calibration data for the diodes, or patterns for driving the ultrasound radiating members.
As illustrated in
Still referring to
One of ordinary skill in the art will recognize that the various embodiments of the isolation pod described above, and illustrated in
While the foregoing detailed description has described several embodiments of the apparatus and methods of the present invention, it is to be understood that the above description is illustrative only and not limited of the disclosed invention. It will be appreciated that the specific dimensions of the various catheters and inner cores can differ from those described above, and that the methods described can be used within any biological conduit in a patient's body, while remaining within the scope of the present invention. Thus, the present invention is to be limited only by the claims that follow.
This application is a continuation of U.S. patent application Ser. No. 14/196,225, filed Mar. 4, 2014, now U.S. Pat. No. 9,415,242, which is a continuation of U.S. patent application Ser. No. 13/431,798, filed Mar. 27, 2012, now U.S. Pat. No. 8,696,612, which is a continuation of U.S. patent application Ser. No. 12/762,254, filed Apr. 16, 2010, now U.S. Pat. No. 8,167,832, which is a divisional of U.S. patent application Ser. No. 11/643,471, filed Dec. 21, 2006, now U.S. Pat. No. 7,727,178, which is a divisional of U.S. patent application Ser. No. 10/309,388, filed Dec. 3, 2002, now U.S. Pat. No. 7,220,239, which claims the benefit of U.S. Provisional Patent Application No. 60/336,744, filed Dec. 3, 2001, U.S. Provisional Patent Application No. 60/336,630, filed Dec. 3, 2001, and U.S. Provisional Patent Application No. 60/394,093, filed Jul. 3, 2002. The entire disclosure of all of these priority documents is hereby incorporated by reference in its entirety.
The invention was made with government support under Grant No. NIH R44 HL057739 awarded by the National Institutes of Health. The government has certain rights in the invention.
Number | Name | Date | Kind |
---|---|---|---|
3352303 | Delaney | Nov 1967 | A |
3430625 | McLeod, Jr. | Mar 1969 | A |
3433226 | Boyd | Mar 1969 | A |
3565062 | Kuris | Feb 1971 | A |
3827115 | Bom | Aug 1974 | A |
3861391 | Antonevich et al. | Jan 1975 | A |
3941122 | Jones | Mar 1976 | A |
3976987 | Anger | Aug 1976 | A |
4040414 | Suroff | Aug 1977 | A |
4192294 | Vasilevsky et al. | Mar 1980 | A |
4309989 | Fahim | Jan 1982 | A |
4319580 | Colley et al. | Mar 1982 | A |
4354502 | Colley et al. | Oct 1982 | A |
4531943 | Van Tassel | Jul 1985 | A |
4549533 | Cain et al. | Oct 1985 | A |
4587975 | Salo et al. | May 1986 | A |
4682596 | Bales et al. | Jul 1987 | A |
4692139 | Stiles | Sep 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4750902 | Wuchinich | Jun 1988 | A |
4754752 | Ginsburg et al. | Jul 1988 | A |
4770185 | Silverstein et al. | Sep 1988 | A |
4808153 | Parisi | Feb 1989 | A |
4821740 | Tachibana et al. | Apr 1989 | A |
4841977 | Griffith et al. | Jun 1989 | A |
4870953 | DonMicheal | Oct 1989 | A |
4920954 | Alliger | May 1990 | A |
4921478 | Solano et al. | May 1990 | A |
4924863 | Sterzer | May 1990 | A |
4933843 | Scheller et al. | Jun 1990 | A |
4936281 | Stasz | Jun 1990 | A |
4948587 | Kost et al. | Aug 1990 | A |
4951677 | Crowley | Aug 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4960109 | Lele | Oct 1990 | A |
4971991 | Umemura et al. | Nov 1990 | A |
5007438 | Tachibana et al. | Apr 1991 | A |
5021044 | Sharkawy | Jun 1991 | A |
5026387 | Thomas | Jun 1991 | A |
5053008 | Bajaj | Oct 1991 | A |
5058570 | Idemoto et al. | Oct 1991 | A |
5059851 | Corl | Oct 1991 | A |
5069664 | Guess | Dec 1991 | A |
5076276 | Sakurai et al. | Dec 1991 | A |
5088499 | Unger | Feb 1992 | A |
5108369 | Ganguly et al. | Apr 1992 | A |
5129883 | Black | Jul 1992 | A |
5149319 | Unger | Sep 1992 | A |
5158071 | Umemura et al. | Oct 1992 | A |
5163421 | Bernstein et al. | Nov 1992 | A |
5163436 | Saitoh et al. | Nov 1992 | A |
5178620 | Eggers et al. | Jan 1993 | A |
5185071 | Serwer et al. | Feb 1993 | A |
5197946 | Tachibana | Mar 1993 | A |
5226421 | Frisbie | Jul 1993 | A |
5250034 | Appling et al. | Oct 1993 | A |
5261291 | Schoch et al. | Nov 1993 | A |
5267954 | Nita | Dec 1993 | A |
5267985 | Shimada | Dec 1993 | A |
5269291 | Carter | Dec 1993 | A |
5271406 | Ganguly | Dec 1993 | A |
5279546 | Mische | Jan 1994 | A |
5282785 | Shapland et al. | Feb 1994 | A |
5286254 | Shapland | Feb 1994 | A |
5295484 | Marcus et al. | Mar 1994 | A |
5304115 | Pflueger | Apr 1994 | A |
5307816 | Hashimoto | May 1994 | A |
5312328 | Nita et al. | May 1994 | A |
5313949 | Yock | May 1994 | A |
5315998 | Tachibana et al. | May 1994 | A |
5318014 | Carter | Jun 1994 | A |
5323769 | Bommannan | Jun 1994 | A |
5326342 | Pflueger | Jul 1994 | A |
5327891 | Rammler | Jul 1994 | A |
5328470 | Nabel | Jul 1994 | A |
5342292 | Nita et al. | Aug 1994 | A |
5344395 | Whalen et al. | Sep 1994 | A |
5344435 | Turner | Sep 1994 | A |
5345940 | Seward | Sep 1994 | A |
5348481 | Oritz | Sep 1994 | A |
5351693 | Taimisto | Oct 1994 | A |
5353798 | Sieben | Oct 1994 | A |
5354279 | Hofling | Oct 1994 | A |
5362309 | Carter | Nov 1994 | A |
5363853 | Lieber | Nov 1994 | A |
5368036 | Tanaka et al. | Nov 1994 | A |
5368557 | Nita | Nov 1994 | A |
5368558 | Nita | Nov 1994 | A |
5370675 | Edwards | Dec 1994 | A |
5372138 | Crowley et al. | Dec 1994 | A |
5380273 | Dubrul et al. | Jan 1995 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5390678 | Gesswein | Feb 1995 | A |
5397293 | Alliger | Mar 1995 | A |
5399158 | Lauer et al. | Mar 1995 | A |
5401237 | Tachibana et al. | Mar 1995 | A |
5405322 | Lennox et al. | Apr 1995 | A |
5421338 | Crowley | Jun 1995 | A |
5423797 | Adrian et al. | Jun 1995 | A |
5431663 | Carter | Jul 1995 | A |
5440914 | Tachibana et al. | Aug 1995 | A |
5445155 | Sieben | Aug 1995 | A |
5447509 | Mills et al. | Sep 1995 | A |
5447510 | Jensen | Sep 1995 | A |
5453575 | O'Donell et al. | Sep 1995 | A |
5456259 | Barlow et al. | Oct 1995 | A |
5458568 | Racchini | Oct 1995 | A |
5462523 | Samson | Oct 1995 | A |
5465726 | Dickinson | Nov 1995 | A |
5474530 | Passafaro | Dec 1995 | A |
5474531 | Carter | Dec 1995 | A |
5498236 | Dubrul et al. | Mar 1996 | A |
5498238 | Shapland | Mar 1996 | A |
5509896 | Carter | Apr 1996 | A |
5514092 | Forman | May 1996 | A |
5520189 | Malinowski | May 1996 | A |
5523058 | Umemura | Jun 1996 | A |
5533986 | Mottola | Jul 1996 | A |
5542917 | Nita et al. | Aug 1996 | A |
5542935 | Unger et al. | Aug 1996 | A |
5558092 | Unger et al. | Sep 1996 | A |
5560362 | Sliwa, Jr. et al. | Oct 1996 | A |
5569197 | Helmus | Oct 1996 | A |
5582586 | Tachibana et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5603327 | Eberle | Feb 1997 | A |
5603694 | Brown | Feb 1997 | A |
5606974 | Castellano | Mar 1997 | A |
5617851 | Lipkovker | Apr 1997 | A |
5618275 | Bock | Apr 1997 | A |
5620409 | Gans et al. | Apr 1997 | A |
5620479 | Diederich | Apr 1997 | A |
5624382 | Oppelt | Apr 1997 | A |
5628728 | Tachibana et al. | May 1997 | A |
5628730 | Shapland | May 1997 | A |
5630837 | Crowley | May 1997 | A |
5648098 | Porter | Jul 1997 | A |
5656016 | Ogden | Aug 1997 | A |
5660180 | Malinowski | Aug 1997 | A |
5660909 | Tachibana et al. | Aug 1997 | A |
5665076 | Roth | Sep 1997 | A |
5681296 | Ishida | Oct 1997 | A |
5695460 | Siegel et al. | Dec 1997 | A |
5697897 | Buchholtz et al. | Dec 1997 | A |
5713831 | Olsson | Feb 1998 | A |
5713848 | Dubrul et al. | Feb 1998 | A |
5720710 | Tachibana et al. | Feb 1998 | A |
5724976 | Hirama et al. | Mar 1998 | A |
5725494 | Brisken | Mar 1998 | A |
5728062 | Brisken | Mar 1998 | A |
5733315 | Burdette et al. | Mar 1998 | A |
5735811 | Brisken | Apr 1998 | A |
5752930 | Baudino et al. | May 1998 | A |
5772632 | Forman | Jun 1998 | A |
5775338 | Hastings | Jul 1998 | A |
5779673 | Roth | Jul 1998 | A |
5807395 | Mulier et al. | Sep 1998 | A |
5817021 | Reichenberger | Oct 1998 | A |
5823962 | Lerch et al. | Oct 1998 | A |
5827203 | Nita | Oct 1998 | A |
5827313 | Ream | Oct 1998 | A |
5834880 | Lewandowski et al. | Nov 1998 | A |
5836896 | Rosenschein | Nov 1998 | A |
5836940 | Gregory | Nov 1998 | A |
5840031 | Crowley | Nov 1998 | A |
5842994 | Tenhoff et al. | Dec 1998 | A |
5846218 | Brisken et al. | Dec 1998 | A |
5876345 | Eaton et al. | Mar 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5916192 | Nita et al. | Jun 1999 | A |
5925016 | Chornenky et al. | Jul 1999 | A |
5928186 | Homsma et al. | Jul 1999 | A |
5931805 | Brisken | Aug 1999 | A |
5934284 | Plaia et al. | Aug 1999 | A |
5935124 | Klumb et al. | Aug 1999 | A |
5938595 | Glass et al. | Aug 1999 | A |
5941868 | Kaplan et al. | Aug 1999 | A |
5957851 | Hossack | Sep 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5957941 | Ream | Sep 1999 | A |
5971949 | Levin et al. | Oct 1999 | A |
5976120 | Chow et al. | Nov 1999 | A |
5984882 | Rosenschein et al. | Nov 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
6001069 | Tachibana et al. | Dec 1999 | A |
6004069 | Sudbury | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6024703 | Zanelli et al. | Feb 2000 | A |
6024718 | Chen et al. | Feb 2000 | A |
6027515 | Cimino | Feb 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6053868 | Geistert et al. | Apr 2000 | A |
6059731 | Seward | May 2000 | A |
6063069 | Cragg et al. | May 2000 | A |
6066123 | Bednarski et al. | May 2000 | A |
6078830 | Levin et al. | Jun 2000 | A |
6088613 | Unger | Jul 2000 | A |
6089573 | Udagawa | Jul 2000 | A |
6096000 | Tachibana et al. | Aug 2000 | A |
6110098 | Renirie | Aug 2000 | A |
6110314 | Nix et al. | Aug 2000 | A |
6113546 | Suorsa | Sep 2000 | A |
6113558 | Rosenchein et al. | Sep 2000 | A |
6113570 | Siegel et al. | Sep 2000 | A |
6117101 | Diederich et al. | Sep 2000 | A |
6120454 | Suorsa | Sep 2000 | A |
6135971 | Hutchinson | Oct 2000 | A |
6135976 | Tachibana et al. | Oct 2000 | A |
6149596 | Bancroft | Nov 2000 | A |
6149599 | Schlesinger | Nov 2000 | A |
6176842 | Tachibana et al. | Jan 2001 | B1 |
6196973 | Lazenby | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6210356 | Anderson et al. | Apr 2001 | B1 |
6210393 | Brisken | Apr 2001 | B1 |
6221038 | Brisken | Apr 2001 | B1 |
6228046 | Brisken | May 2001 | B1 |
6231516 | Keilman | May 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6238347 | Nix et al. | May 2001 | B1 |
6270460 | McCartan et al. | Aug 2001 | B1 |
6277077 | Brisken et al. | Aug 2001 | B1 |
6283920 | Eberle | Sep 2001 | B1 |
6287271 | Dubrul et al. | Sep 2001 | B1 |
6296610 | Schneider et al. | Oct 2001 | B1 |
6296619 | Brisken et al. | Oct 2001 | B1 |
6299597 | Buscemi et al. | Oct 2001 | B1 |
6309370 | Haim et al. | Oct 2001 | B1 |
6312402 | Hansmann | Nov 2001 | B1 |
6361500 | Masters | Mar 2002 | B1 |
6361554 | Brisken | Mar 2002 | B1 |
6366719 | Heath et al. | Apr 2002 | B1 |
6372498 | Newman et al. | Apr 2002 | B2 |
6379320 | Lafon et al. | Apr 2002 | B1 |
6387035 | Jung, Jr. et al. | May 2002 | B1 |
6387052 | Quinn | May 2002 | B1 |
6391042 | Cimino | May 2002 | B1 |
6394956 | Chandrasekaran et al. | May 2002 | B1 |
6398772 | Bond et al. | Jun 2002 | B1 |
6398792 | O'Connor | Jun 2002 | B1 |
6416740 | Unger | Jul 2002 | B1 |
6423026 | Gesswein et al. | Jul 2002 | B1 |
6433464 | Jones | Aug 2002 | B2 |
6437487 | Mohr, III | Aug 2002 | B1 |
6454737 | Nita et al. | Sep 2002 | B1 |
6454757 | Nita et al. | Sep 2002 | B1 |
6456863 | Levin | Sep 2002 | B1 |
6461314 | Pant et al. | Oct 2002 | B1 |
6464680 | Brisken et al. | Oct 2002 | B1 |
6471683 | Drasier et al. | Oct 2002 | B2 |
6478765 | Siegel et al. | Nov 2002 | B2 |
6494891 | Cornish et al. | Dec 2002 | B1 |
6503202 | Hossack et al. | Jan 2003 | B1 |
6506584 | Chandler et al. | Jan 2003 | B1 |
6508775 | McKenzie et al. | Jan 2003 | B2 |
6511478 | Burnside et al. | Jan 2003 | B1 |
6524251 | Rabiner et al. | Feb 2003 | B2 |
6524271 | Brisken et al. | Feb 2003 | B2 |
6524300 | Meglin | Feb 2003 | B2 |
6537224 | Mauchamp et al. | Mar 2003 | B2 |
6537306 | Burdette et al. | Mar 2003 | B1 |
6542767 | McNichols et al. | Apr 2003 | B1 |
6551337 | Rabiner et al. | Apr 2003 | B1 |
6558366 | Drasler et al. | May 2003 | B1 |
6560837 | Hodjat et al. | May 2003 | B1 |
6561998 | Roth | May 2003 | B1 |
6562021 | Derbin et al. | May 2003 | B1 |
6565552 | Barbut | May 2003 | B1 |
6575922 | Fearnside et al. | Jun 2003 | B1 |
6575956 | Brisken et al. | Jun 2003 | B1 |
6579277 | Rabiner et al. | Jun 2003 | B1 |
6579279 | Rabiner et al. | Jun 2003 | B1 |
6582392 | Bennett et al. | Jun 2003 | B1 |
6585763 | Keilman | Jul 2003 | B1 |
6589182 | Loftman | Jul 2003 | B1 |
6589253 | Cornish et al. | Jul 2003 | B1 |
6599288 | Maguire | Jul 2003 | B2 |
6605084 | Acker et al. | Aug 2003 | B2 |
6607502 | Maguire et al. | Aug 2003 | B1 |
6623444 | Babaev | Sep 2003 | B2 |
6635017 | Moehring et al. | Oct 2003 | B1 |
6635046 | Barbut | Oct 2003 | B1 |
6645150 | Angelsen et al. | Nov 2003 | B2 |
6647755 | Rabiner et al. | Nov 2003 | B2 |
6652547 | Rabiner et al. | Nov 2003 | B2 |
6660013 | Rabiner et al. | Dec 2003 | B2 |
6663613 | Evans et al. | Dec 2003 | B1 |
6676626 | Bennett et al. | Jan 2004 | B1 |
6682502 | Bond et al. | Jan 2004 | B2 |
6689086 | Nita et al. | Feb 2004 | B1 |
6695781 | Rabiner et al. | Feb 2004 | B2 |
6695782 | Ranucci et al. | Feb 2004 | B2 |
6695785 | Brisken et al. | Feb 2004 | B2 |
6711953 | Hayashi et al. | Mar 2004 | B2 |
6723063 | Zhang et al. | Apr 2004 | B1 |
6723064 | Babaev | Apr 2004 | B2 |
6726698 | Cimino | Apr 2004 | B2 |
6730048 | Hare et al. | May 2004 | B1 |
6733451 | Rabiner et al. | May 2004 | B2 |
6740040 | Mandrusov et al. | May 2004 | B1 |
6758857 | Cioanta | Jul 2004 | B2 |
6767345 | St. Germain et al. | Jul 2004 | B2 |
6824515 | Suorsa et al. | Nov 2004 | B2 |
6824575 | Otomo et al. | Nov 2004 | B1 |
6830577 | Nash et al. | Dec 2004 | B2 |
6849062 | Kantor | Feb 2005 | B2 |
6855123 | Nita | Feb 2005 | B2 |
6866670 | Rabiner et al. | Mar 2005 | B2 |
6905505 | Dodson, Jr. et al. | Jun 2005 | B2 |
6921371 | Wilson | Jul 2005 | B2 |
6929633 | Evans et al. | Aug 2005 | B2 |
6942620 | Nita et al. | Sep 2005 | B2 |
6942677 | Nita et al. | Sep 2005 | B2 |
6945937 | Culp et al. | Sep 2005 | B2 |
6958040 | Oliver | Oct 2005 | B2 |
6979293 | Hansmann et al. | Dec 2005 | B2 |
6985771 | Fischell et al. | Jan 2006 | B2 |
7077820 | Kadziauskas et al. | Jul 2006 | B1 |
7089063 | Lesh et al. | Aug 2006 | B2 |
7137963 | Nita et al. | Nov 2006 | B2 |
7141044 | Gentsler | Nov 2006 | B2 |
7166098 | Steward et al. | Jan 2007 | B1 |
7186246 | Bennett et al. | Mar 2007 | B2 |
7220233 | Nita et al. | May 2007 | B2 |
7220239 | Wilson et al. | May 2007 | B2 |
7309334 | von Hoffmann | Dec 2007 | B2 |
7335180 | Nita et al. | Feb 2008 | B2 |
7341569 | Soltani et al. | Mar 2008 | B2 |
7384407 | Rodriguez et al. | Jun 2008 | B2 |
7413556 | Zhang et al. | Aug 2008 | B2 |
7503895 | Rabiner et al. | Mar 2009 | B2 |
7540852 | Nita et al. | Jun 2009 | B2 |
7567016 | Lu et al. | Jul 2009 | B2 |
7604608 | Nita et al. | Oct 2009 | B2 |
7621902 | Nita et al. | Nov 2009 | B2 |
7621929 | Nita et al. | Nov 2009 | B2 |
7648478 | Soltani et al. | Jan 2010 | B2 |
7715908 | Moran et al. | May 2010 | B2 |
7727178 | Wilson | Jun 2010 | B2 |
7758509 | Angelsen et al. | Jul 2010 | B2 |
7771372 | Wilson | Aug 2010 | B2 |
7774933 | Wilson et al. | Aug 2010 | B2 |
7789830 | Fujita et al. | Sep 2010 | B2 |
7818854 | Wilson | Oct 2010 | B2 |
7828754 | Abe et al. | Nov 2010 | B2 |
7828762 | Wilson | Nov 2010 | B2 |
7862576 | Gurm | Jan 2011 | B2 |
7901359 | Mandrusov et al. | Mar 2011 | B2 |
7914509 | Bennett et al. | Mar 2011 | B2 |
8012092 | Powers et al. | Sep 2011 | B2 |
8062566 | Nita et al. | Nov 2011 | B2 |
8123789 | Khanna | Feb 2012 | B2 |
8152753 | Nita et al. | Apr 2012 | B2 |
8167831 | Wilson | May 2012 | B2 |
8192363 | Soltani et al. | Jun 2012 | B2 |
8696612 | Wilson et al. | Apr 2014 | B2 |
8740835 | Soltani et al. | Jun 2014 | B2 |
8764700 | Zhang et al. | Jul 2014 | B2 |
8819928 | Nix et al. | Sep 2014 | B2 |
9044568 | Wilcox et al. | Jun 2015 | B2 |
9107590 | Hansmann et al. | Aug 2015 | B2 |
9192566 | Soltani et al. | Nov 2015 | B2 |
9415242 | Wilson et al. | Aug 2016 | B2 |
20010000791 | Suorsa et al. | May 2001 | A1 |
20010007861 | Newman | Jul 2001 | A1 |
20010007940 | Tu et al. | Jul 2001 | A1 |
20010025190 | Weber et al. | Sep 2001 | A1 |
20010037106 | Shadduck | Nov 2001 | A1 |
20010039419 | Francischelli et al. | Nov 2001 | A1 |
20010041842 | Eberle | Nov 2001 | A1 |
20020000763 | Jones | Jan 2002 | A1 |
20020019644 | Hastings | Feb 2002 | A1 |
20020032394 | Brisken et al. | Mar 2002 | A1 |
20020045890 | Celliers et al. | Apr 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020068869 | Brisken et al. | Jun 2002 | A1 |
20020077550 | Rabiner et al. | Jun 2002 | A1 |
20020082238 | Newman et al. | Jun 2002 | A1 |
20020087083 | Nix | Jul 2002 | A1 |
20020099292 | Brisken et al. | Jul 2002 | A1 |
20020123787 | Weiss | Sep 2002 | A1 |
20020133111 | Shadduck | Sep 2002 | A1 |
20020188276 | Evans et al. | Dec 2002 | A1 |
20020193708 | Thompson et al. | Dec 2002 | A1 |
20030036705 | Hare et al. | Feb 2003 | A1 |
20030040501 | Newman et al. | Feb 2003 | A1 |
20030050662 | Don Michael | Mar 2003 | A1 |
20030065263 | Hare et al. | Apr 2003 | A1 |
20030069525 | Brisken et al. | Apr 2003 | A1 |
20030083608 | Evans et al. | May 2003 | A1 |
20030109812 | Cort et al. | Jun 2003 | A1 |
20030135262 | Dretler et al. | Jul 2003 | A1 |
20030163147 | Hare et al. | Aug 2003 | A1 |
20030236539 | Rabiner et al. | Dec 2003 | A1 |
20040001809 | Brisken et al. | Jan 2004 | A1 |
20040015122 | Zhang et al. | Jan 2004 | A1 |
20040019318 | Wilson et al. | Jan 2004 | A1 |
20040024393 | Nita et al. | Feb 2004 | A1 |
20040039311 | Nita et al. | Feb 2004 | A1 |
20040049148 | Rodriguez et al. | Mar 2004 | A1 |
20040059313 | Anderson et al. | Mar 2004 | A1 |
20040068189 | Wilson et al. | Apr 2004 | A1 |
20040097996 | Hare et al. | May 2004 | A1 |
20040122354 | Semba | Jun 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138570 | Nita et al. | Jul 2004 | A1 |
20040162571 | Rabiner et al. | Aug 2004 | A1 |
20040171981 | Buffen et al. | Sep 2004 | A1 |
20040220514 | Cafferata | Nov 2004 | A1 |
20040236350 | Bolduc et al. | Nov 2004 | A1 |
20040243062 | Henry | Dec 2004 | A1 |
20040255957 | Cafferata | Dec 2004 | A1 |
20040265393 | Unger et al. | Dec 2004 | A1 |
20050021063 | Hall et al. | Jan 2005 | A1 |
20050043629 | Rabiner et al. | Feb 2005 | A1 |
20050043753 | Rabiner et al. | Feb 2005 | A1 |
20050096669 | Rabiner et al. | May 2005 | A1 |
20050113688 | Nita et al. | May 2005 | A1 |
20050119679 | Rabiner et al. | Jun 2005 | A1 |
20050124877 | Nita et al. | Jun 2005 | A1 |
20050137520 | Rule et al. | Jun 2005 | A1 |
20050187513 | Rabiner et al. | Aug 2005 | A1 |
20050187514 | Rabiner et al. | Aug 2005 | A1 |
20050192558 | Soltani et al. | Sep 2005 | A1 |
20050197619 | Rule et al. | Sep 2005 | A1 |
20050209578 | Evans et al. | Sep 2005 | A1 |
20050215942 | Abrahamson et al. | Sep 2005 | A1 |
20050215946 | Hansmann et al. | Sep 2005 | A1 |
20050216044 | Hong | Sep 2005 | A1 |
20050256410 | Rabiner et al. | Nov 2005 | A1 |
20050288695 | Jenson et al. | Dec 2005 | A1 |
20060069303 | Couvillon | Mar 2006 | A1 |
20060106308 | Hansmann et al. | May 2006 | A1 |
20060116610 | Hare et al. | Jun 2006 | A1 |
20060173387 | Hansmann et al. | Aug 2006 | A1 |
20060184070 | Hansmann et al. | Aug 2006 | A1 |
20070005121 | Khanna | Jan 2007 | A1 |
20070037119 | Pal et al. | Feb 2007 | A1 |
20070038158 | Nita et al. | Feb 2007 | A1 |
20070066978 | Schafer et al. | Mar 2007 | A1 |
20070112268 | Zhang et al. | May 2007 | A1 |
20070225619 | Rabiner et al. | Sep 2007 | A1 |
20070239027 | Nita | Oct 2007 | A1 |
20070255252 | Mehta | Nov 2007 | A1 |
20070265560 | Soltani et al. | Nov 2007 | A1 |
20080045865 | Kislev | Feb 2008 | A1 |
20080065014 | McCrystle et al. | Mar 2008 | A1 |
20080109029 | Gurm | May 2008 | A1 |
20080146918 | Magnin et al. | Jun 2008 | A1 |
20080154181 | Khanna | Jun 2008 | A1 |
20080167602 | Nita et al. | Jul 2008 | A1 |
20080171965 | Soltani et al. | Jul 2008 | A1 |
20080172067 | Nita et al. | Jul 2008 | A1 |
20080194954 | Matsunaga et al. | Aug 2008 | A1 |
20080221506 | Rodriguez et al. | Sep 2008 | A1 |
20080262350 | Unger | Oct 2008 | A1 |
20080306499 | Katoh et al. | Dec 2008 | A1 |
20080319355 | Nita | Dec 2008 | A1 |
20080319376 | Wilcox et al. | Dec 2008 | A1 |
20090018472 | Soltani et al. | Jan 2009 | A1 |
20090073455 | Onimura | Mar 2009 | A1 |
20090105597 | Abraham | Apr 2009 | A1 |
20090112150 | Unger et al. | Apr 2009 | A1 |
20090209900 | Carmeli et al. | Aug 2009 | A1 |
20090216246 | Nita et al. | Aug 2009 | A1 |
20090221902 | Myhr | Sep 2009 | A1 |
20100010393 | Duffy et al. | Jan 2010 | A1 |
20100022920 | Nita et al. | Jan 2010 | A1 |
20100022944 | Wilcox | Jan 2010 | A1 |
20100023036 | Nita et al. | Jan 2010 | A1 |
20100023037 | Nita et al. | Jan 2010 | A1 |
20100049209 | Nita et al. | Feb 2010 | A1 |
20100063413 | Volz | Mar 2010 | A1 |
20100063414 | Volz | Mar 2010 | A1 |
20100081934 | Hansmann et al. | Apr 2010 | A1 |
20100204582 | Lu | Aug 2010 | A1 |
20100210940 | Bradley et al. | Aug 2010 | A1 |
20100222715 | Nita | Sep 2010 | A1 |
20100256616 | Katoh et al. | Oct 2010 | A1 |
20100262215 | Gertner | Oct 2010 | A1 |
20100292685 | Katoh et al. | Nov 2010 | A1 |
20110160621 | Nita | Jun 2011 | A1 |
20110288449 | Schenkengel | Nov 2011 | A1 |
20110313328 | Nita | Dec 2011 | A1 |
20110319927 | Nita | Dec 2011 | A1 |
20120016272 | Nita et al. | Jan 2012 | A1 |
20120041307 | Patel et al. | Feb 2012 | A1 |
20120059285 | Soltani et al. | Mar 2012 | A1 |
20120078140 | Nita | Mar 2012 | A1 |
20120123273 | Okuno et al. | May 2012 | A1 |
20120172795 | Sandhu et al. | Jul 2012 | A1 |
20120172858 | Harrison et al. | Jul 2012 | A1 |
20120179073 | Nita | Jul 2012 | A1 |
20120197277 | Stinis | Aug 2012 | A1 |
20120289889 | Genstler et al. | Nov 2012 | A1 |
20120330141 | Brown et al. | Dec 2012 | A1 |
20140210631 | Zavis | Jul 2014 | A1 |
20140236118 | Unser et al. | Aug 2014 | A1 |
20140343483 | Zhang et al. | Nov 2014 | A1 |
20160361528 | Kanz et al. | Dec 2016 | A1 |
Number | Date | Country |
---|---|---|
40 05 743 | Aug 1991 | DE |
0 529 675 | Mar 1993 | EP |
0 629 382 | Dec 1994 | EP |
0 744 189 | Nov 1996 | EP |
0 746 245 | Dec 1996 | EP |
1 090 658 | Apr 2001 | EP |
1 453 425 | Sep 2004 | EP |
1 647 232 | Apr 2006 | EP |
52-115591 | Sep 1977 | JP |
02-180275 | Jul 1990 | JP |
WO 92000113 | Jan 1992 | WO |
WO 95001751 | Jan 1995 | WO |
WO 95005866 | Mar 1995 | WO |
WO 95026777 | Oct 1995 | WO |
WO 96004955 | Feb 1996 | WO |
WO 96027341 | Sep 1996 | WO |
WO 96029935 | Oct 1996 | WO |
WO 96036286 | Nov 1996 | WO |
WO 97019645 | Jun 1997 | WO |
WO 98011826 | Mar 1998 | WO |
WO 89004142 | May 1998 | WO |
WO 98018391 | May 1998 | WO |
WO 98048711 | Nov 1998 | WO |
WO 98056462 | Dec 1998 | WO |
WO 99032184 | Jul 1999 | WO |
WO 99033500 | Jul 1999 | WO |
WO 99034858 | Jul 1999 | WO |
WO 99039647 | Aug 1999 | WO |
WO 99044512 | Sep 1999 | WO |
WO 00000095 | Jan 2000 | WO |
WO 00038580 | Jul 2000 | WO |
WO 00069341 | Nov 2000 | WO |
WO 01054754 | Aug 2001 | WO |
WO 01087174 | Nov 2001 | WO |
WO 01095788 | Dec 2001 | WO |
WO 02013678 | Feb 2002 | WO |
WO 02015803 | Feb 2002 | WO |
WO 02015804 | Feb 2002 | WO |
WO 03051208 | Jun 2003 | WO |
WO 2005027756 | Mar 2005 | WO |
WO 2005084552 | Sep 2005 | WO |
WO 2005084553 | Sep 2005 | WO |
WO 2008052186 | May 2008 | WO |
WO 2015074036 | May 2015 | WO |
Entry |
---|
Chamsuddin et al., “Catheter-directed Thrombolysis with the Endowave System in the Treatment of Acute Massive Pulmonary Embolism: A Retrospective Multicenter Case Series,” Journal of Vascular and Interventional Radiology, Mar. 2008, vol. 19, No. 3, pp. 372-376. |
Hynynen et al.; “Small Cylindrical Ultrasound Sources for Induction of Hyperthermia Via Body Cavities or Interstitial Implants”, Arizona Cancer Center and Department of Radiation Oncology, University of Arizona Health Sciences Center; vol. 9, No. 2, 1993 pp. 263-274. |
International Search Report and Written Opinion in Application No. PCT/US02/038527, dated Jul. 25, 2003. |
Lee et al.; “Arrays of Multielement Ultrasound Applicators for Interstitial Hyperthermia”; IEEE Transactios on biomedical Engineering; vol. 46, No. 7, Jul. 1999, pp. 880-890. |
Lin et al., “Comparison of Percutaneous Ultrasound-Accelerated Thrombolysis versus Catheter-Directed Thrombolysis in Patients with Acute Massive Pulmonary Embolism,” Vascular, 2009, vol. 17, No. 3, pp. S137-S147. |
Official Communication in European Application No. 05027733.4, dated Sep. 23, 2009. |
Schäfer et al., “Influence of Ultrasound Operating Parameters on Ultrasound-Induced Thrombolysis In Vitro,” Ultrasound in Medicine and Biology, vol. 31, No. 6, Mar. 2005, pp, 841-847. |
Tsetis et al., “Potential Benefits From Heating the High-Dose Rtpa Boluses Used in Catheter-Directed Thrombolysis for Acute/Subacute Lower Limb Ischemia”, Journal of Endovascular Therapy, 2003, vol. 10, pp. 739-744. |
Number | Date | Country | |
---|---|---|---|
20170007815 A1 | Jan 2017 | US |
Number | Date | Country | |
---|---|---|---|
60394093 | Jul 2002 | US | |
60336744 | Dec 2001 | US | |
60336630 | Dec 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11643471 | Dec 2006 | US |
Child | 12762254 | US | |
Parent | 10309388 | Dec 2002 | US |
Child | 11643471 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14196225 | Mar 2014 | US |
Child | 15207371 | US | |
Parent | 13431798 | Mar 2012 | US |
Child | 14196225 | US | |
Parent | 12762254 | Apr 2010 | US |
Child | 13431798 | US |